Progressive Improvement in 5-Year Survival Rates for Extremity Soft Tissue Sarcomas from 1999 to 2019
Table 3
Multivariate 5-year survival analysis.
Variablea
Hazard ratio (95% CI)
Total number
Number of events
Median survival time (months)
Period of diagnosis
2013–2019
Referent
2,187
493
NAb
2006–2012
2.1 (1.9, 2.3)
<0.001
2,074
809
63.0 (59.1, 66.0)
1999–2005
3.4 (3.0, 3.8)
<0.001
1,393
734
45.0 (40.8, 49.2)
Age group (years)
<30
Referent
419
82
NAb
30–59
1.9 (1.5, 2.4)
<0.001
2,533
666
NAb
≥60
3.9 (3.0, 5.0)
<0.001
2,702
1,288
51.0 (47.7, 54.3)
Marital status
Married
Referent
3,206
1,049
NAb
Single
1.3 (1.2, 1.5)
<0.001
1,210
398
NAb
Other
1.3 (1.1, 1.4)
<0.001
1,034
529
45.0 (40.2, 49.8)
Tumor size (cm)
<5
Referent
1,702
413
NAb
5–10
1.5 (1.3, 1.7)
<0.001
1,759
631
70.0 (67.5, 72.5)
>10
2.5 (2.2, 2.8)
<0.001
2,193
992
52.0 (47.3, 50.3)
Grade
I
Referent
1,130
173
NAb
II
1.9 (1.5, 2.3)
<0.001
1,229
305
NAb
III
3.3 (2.8, 4.0)
<0.001
3,295
1,558
47.0 (43.7, 50.3)
Metastasis
No
Referent
4,404
1,299
NAb
Yes
1.4 (1.3, 1.6)
<0.001
1,250
727
33.0 (29.1, 36.9)
Histology
NOS
Referent
332
175
43.0 (32.7, 53.3)
Fibromatous
0.76 (0.64, 0.91)
0.002
1,292
527
63.0 (58.1, 67.9)
Myxomatous
0.76 (0.55, 1.1)
0.099
143
46
72.0 (60.3, 83.7)
Lipomatous
0.55 (0.45, 0.67)
<0.001
1,620
366
NAb
Myomatous
0.99 (0.82, 1.2)
0.941
725
306
56.0 (48.1, 63.9)
Synovial
0.95 (0.74, 1.2)
0.665
322
112
NAb
All other types
1.1 (0.88, 1.3)
0.564
1,220
504
54.0 (46.8, 61.2)
Surgery
No
Referent
307
228
10.0 (7.8, 12.2)
Yes
0.28 (0.24, 0.33)
<0.001
5,347
1,808
72.0 (70.5, 73.5)
Radiation
No
Referent
2,436
822
NAb
Yes
0.73 (0.66, 0.80)
<0.001
3,218
1,214
65.0 (62.4, 67.6)
Chemotherapy
No
Referent
4,498
1,455
NAb
Yes
1.0 (0.93, 1.2)
0.444
1,156
581
40.0 (35.7, 44.3)
aPrimary site, race, ethnicity, and sex were not included in multivariate Cox proportional hazard analysis because variables were not statistically significant on univariate analyses. CI, confidence interval; NOS, not otherwise specified. bUnable to calculate due to >50% survival.
